Abstract
Individuals with early Alzheimers disease (AD) suffer from a selective and profound failure to form new memories. A novel molecular mechanism with implications for therapeutics and diagnostics is now emerging in which the specificity of AD for memory derives from disruption of plasticity at synapses targeted by toxic Aβ oligomers (also known as ADDLs). ADDLs accumulate in AD brain and constitute long-lived alternatives to the disease-defining Aβ fibrils deposited in amyloid plaques. The AD-like cellular pathologies induced by ADDLs suggest their impact could provide a unifying mechanism for AD pathogenesis, explaining why early stage disease is specific for memory and accounting for major facets of AD neuropathology. Discovery of these new toxins has provided an appealing target for disease-modifying immunotherapy. For optimal protection against these toxins, antibodies should bind to the pathological oligomers without being depleted by their monomeric subunits, which are rapidly generated by membrane protein turnover. A solution to this problem is likely to come from the continued development of conformation-specific antibodies, as described here. Prototype conformation-specific antibodies, not yet in the clinic, have been introduced and utilized in multiple applications for their ability to bind with high specificity and affinity to ADDLs. It can be anticipated that further development of such antibodies for use in clinical trials will come in the near future.
Keywords: Alzheimer's disease, ADDL, oligomer, synapse, neurodegeneration, CNS neurons, diseasemodifying therapeutics, diagnostics
CNS & Neurological Disorders - Drug Targets
Title: Targeting Generation of Antibodies Specific to Conformational Epitopes of Amyloid β-Derived Neurotoxins
Volume: 8 Issue: 1
Author(s): Mary P. Lambert, Pauline T. Velasco, Kirsten L. Viola and William L. Klein
Affiliation:
Keywords: Alzheimer's disease, ADDL, oligomer, synapse, neurodegeneration, CNS neurons, diseasemodifying therapeutics, diagnostics
Abstract: Individuals with early Alzheimers disease (AD) suffer from a selective and profound failure to form new memories. A novel molecular mechanism with implications for therapeutics and diagnostics is now emerging in which the specificity of AD for memory derives from disruption of plasticity at synapses targeted by toxic Aβ oligomers (also known as ADDLs). ADDLs accumulate in AD brain and constitute long-lived alternatives to the disease-defining Aβ fibrils deposited in amyloid plaques. The AD-like cellular pathologies induced by ADDLs suggest their impact could provide a unifying mechanism for AD pathogenesis, explaining why early stage disease is specific for memory and accounting for major facets of AD neuropathology. Discovery of these new toxins has provided an appealing target for disease-modifying immunotherapy. For optimal protection against these toxins, antibodies should bind to the pathological oligomers without being depleted by their monomeric subunits, which are rapidly generated by membrane protein turnover. A solution to this problem is likely to come from the continued development of conformation-specific antibodies, as described here. Prototype conformation-specific antibodies, not yet in the clinic, have been introduced and utilized in multiple applications for their ability to bind with high specificity and affinity to ADDLs. It can be anticipated that further development of such antibodies for use in clinical trials will come in the near future.
Export Options
About this article
Cite this article as:
Lambert P. Mary, Velasco T. Pauline, Viola L. Kirsten and Klein L. William, Targeting Generation of Antibodies Specific to Conformational Epitopes of Amyloid β-Derived Neurotoxins, CNS & Neurological Disorders - Drug Targets 2009; 8 (1) . https://dx.doi.org/10.2174/187152709787601876
DOI https://dx.doi.org/10.2174/187152709787601876 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetics of Ion Channels in Sudden Unexplained Death Syndrome: Moving Beyond Idiopathic Reactions To Personalized Risk Assessment
Current Pharmacogenomics and Personalized Medicine Cardiovascular Disease in Patients with Diabetic Nephropathy
Current Molecular Medicine Does Oral Metoprolol have Any Effect on the Functional Parameters and Perfusion Defects of the Left Ventricle?
Current Medical Imaging Perioperative Considerations in Diabetic Patients
Current Diabetes Reviews Genetics of Hypertrophic and Dilated Cardiomyopathy
Current Pharmaceutical Biotechnology Tracking Stem Cell Therapy in the Myocardium: Applications of Positron Emission Tomography
Current Pharmaceutical Design Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Epidermolysis Bullosa: Pediatric Perspectives
Current Pediatric Reviews Cosignaling Molecules Around LIGHT-HVEM-BTLA: From Immune Activation to Therapeutic Targeting
Current Molecular Medicine Mitochondria Damage in the Pathogenesis of Diabetic Retinopathy and in the Metabolic Memory Associated with its Continued Progression
Current Medicinal Chemistry Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?
Current Drug Targets Cardiovascular Complications in Diabetes: Lessons from Animal Models
Current Medicinal Chemistry The STAT3 Inhibitor Stattic Impairs Cardiomyocyte Mitochondrial Function Through Increased Reactive Oxygen Species Formation
Current Pharmaceutical Design Regulatory Mechanisms of Calcineurin Phosphatase Activity
Current Medicinal Chemistry Cardiovascular Effects of Ghrelin and Growth Hormone Secretagogues
Cardiovascular & Hematological Disorders-Drug Targets Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection
Current Pharmaceutical Design Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Current Gene Therapy Role of Heme Oxygenase-1 in Cardiovascular Function
Current Pharmaceutical Design ABCC6 as a Target in Pseudoxanthoma Elasticum
Current Drug Targets